Merck (MRK) closed the most recent trading day at $81.52, moving -2.57% from the previous trading session. This change lagged the S&P 500's 0.4% loss on the day. Meanwhile, the Dow experienced a drop ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Private equity work is up year-over-year, but tariffs, inflation and valuations continue to be an issue for dealmakers.

TOKYO -- Roughly 2.5 million doses of oral COVID-19 medication bought by the Japanese government during the pandemic expired ...

Merck & Co., Inc. (NYSE:MRK), one of the largest pharmaceutical companies in the world, has lost 15% year-to-date on the ...

Merck, a leading science and technology company, has launched the AAW™ Automated Assay Workstation, a solution powered by ...

NHS England has agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced its once-monthly PrEP ...

A report on July 14, 2025 shows that Representative Julie Johnson from Texas purchase stock in 3M MMM -0.70% Get Free Report , valued between $2,002 and $30,000. According to the July filing, the ...

Adagene Inc. (ADAG) on Tuesday said that it received directions from the U.S. Food and Drug Administration on further clinical development of its investigational drug Muzastotug in combination with ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.